Kyverna Therapeutics Inc (KYTX) FinancialsKYTXKyverna Therapeutics Inc

Evaluating the bottom line, Kyverna Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -87.24%, provide a clear picture of how effectively KYTX converts its operational activities into shareholder value.

In the context of the broader market, KYTX competes directly with industry leaders such as ZURA and GALT. With a market capitalization of $333.34M, it holds a significant position in the sector. When comparing efficiency, KYTX's gross margin of N/A stands against ZURA's N/A and GALT's N/A. Such benchmarking helps identify whether Kyverna Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Kyverna has reported consistent net losses, with Q1 2026 showing a net loss of $39,728,000 and an EPS of -0.66. The company's current ratio is strong at 8.15, indicating good short-term liquidity, but the overall financial health is concerning due to persistent losses and a negative P/E ratio of -2.32.